Sort
10,766 grants matching “checkpoint inhibitor”
Project 1: Targeting Tumor Phospholipase PLA2G10 for Cancer Immunotherapy
$411,417Kurt A Schalper · Yale University · P50 · FY2025 · CA
Coordinating tumor differentiation and immune suppression with the metabolic state and treatment outcome
$411,278Hans Ragnar Widlund · Brigham And Women'S Hospital · R01 · FY2017 · CA
Spatiotemporal control of insulin signaling by mitotic regulators
$411,250Eunhee Choi · Columbia University Health Sciences · R01 · FY2022 · DK
Spatiotemporal control of insulin signaling by mitotic regulators
$411,250Eunhee Choi · Columbia University Health Sciences · R01 · FY2023 · DK
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer
$411,213Kent W Mouw · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma
$410,835Hikmat Al-Ahmadie · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma
$410,835Hikmat Al-Ahmadie · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma
$410,835Hikmat Al-Ahmadie · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA
Targeting exosomal PDL1 to improve immunotherapy
$410,622Wei Guo · Wistar Institute · P50 · FY2022 · CA
Epigenetic Reprogramming of T cell Exhaustion To Enhance Tumor Immunotherapy
$410,606Benjamin Alan Youngblood · St. Jude Children'S Research Hospital · R01 · FY2021 · CA
Epigenetic Reprogramming of T cell Exhaustion To Enhance Tumor Immunotherapy
$410,606Benjamin Alan Youngblood · St. Jude Children'S Research Hospital · R01 · FY2020 · CA
Targeting mechanisms of immune evasion in chemotherapy-induced senescent cells
$410,550James Jackson · Tulane University Of Louisiana · R01 · FY2024 · CA
Using dietary glutamine supplementation for melanoma prevention and targeted therapy
$410,444Mei Kong · University Of California-Irvine · R01 · FY2023 · CA
Project 4: Translation and preclinical studies of a personalized pancreas cancer vaccine
$410,431William E Gillanders · Washington University · P50 · FY2020 · CA
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma
$410,395Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2024 · CA
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor
$410,323David John Tweardy · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
In situ radioimmunotherapy to maximize the engagement of conventional type 1 dendritic cells against non-T cell-inflamed tumors
$410,221Fumito Ito · Roswell Park Cancer Institute Corp · R01 · FY2021 · CA
Engineering Nanomaterials to Prime Immunity
$410,177James J. Moon · University Of Michigan At Ann Arbor · R01 · FY2021 · CA
Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunity
$410,082Venuprasad K Poojary · Ut Southwestern Medical Center · R01 · FY2023 · AI
Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunity
$410,082Venuprasad K Poojary · Ut Southwestern Medical Center · R01 · FY2024 · AI
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy
$410,049Xiang-Yang Wang · Virginia Commonwealth University · R01 · FY2021 · CA
The coordination of cell size control and cell cycle regulation at developmental extremes
$410,000Amanda A Amodeo · Dartmouth College · R35 · FY2024 · GM
The coordination of cell size control and cell cycle regulation at developmental extremes
$410,000Amanda A Amodeo · Dartmouth College · R35 · FY2025 · GM
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapy
$409,560Gen-Sheng Feng · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2024 · AG
MMS22L loss and PARP inhibition in prostate cancer
$409,463Li Jia · Brigham And Women'S Hospital · R01 · FY2023 · CA